While the initial research on Dihexas mechanism is promising, ongoing studies are crucial to fully understand the full effects of Dihexa and its potential applications in different neurological conditions, such as Alzheimers disease
However, the largest Phase IIb trial involving 536 subjects failed to demonstrate statistically significant weight loss compared to placebo at the primary 12-week endpoint, leading Metabolic Pharmaceuticals to terminate development in 2007
AOD 9604 Studies on Obesity Models In obese murine models, both growth hormone and AOD 9604 have been linked to reductions in body fat mass, though the outcomes appeared different in lean models
This variant has higher levels of thyroid autoantibodies in circulation
Safety, Stability, and Storage This copper peptide has a favorable safety profile across decades of research